A new spinout from Monash University in Melbourne, Australia, is tackling biology to better understand immune cell function and to find targets that were thought to be undruggable. Onko-innate co-founders Jai Rautela and Nicholas Huntington first worked together at Huntington’s lab at the Walter and Eliza Hall Institute of Medical Research (WEHI) in Melbourne where they studied the role of natural killer (NK) cells in tumor immunology and discovered some interesting regulatory pathways for cytokine responses. Read More
Researchers from Shanghai Institute of Materia Medica of the Chinese Academy of Sciences and affiliated organizations published preclinical data for a new class of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors being developed as candidates for the treatment of lymphoma. Read More
Recent findings have suggested GAL-201 from Galimedix Therapeutics Inc. is a robust oral candidate to treat Alzheimer’s disease (AD). GAL-201 binds to the misfolded form of amyloid-β (Aβ) monomers, thus preventing its aggregation and formation of neurotoxic oligomers and protofibrils. Read More
Work was conducted at the University of Bialystok to study plasma galectins (1, 2 and 12) plus serum and urinary levels of tumor necrosis factor (TNF), endothelin-1 (ET-1) and α1-acid-glycoprotein (α1AGP) in regards to the relationship between psoriasis and its related complications. Read More
The small-molecule steroid sulfatase (STS) inhibitor STX-64 (ONESTX-1, irosustat) previously showed a good safety and tolerability profile in several phase I and II clinical trials that evaluated the candidate for oncology indications. Read More
Eilean Therapeutics LLC has announced clearance by the Human Research Ethics Committee in Australia for a first-in-human phase I trial of balamenib (ZE63-0302), an oral small-molecule inhibitor of the menin-KMT2A interaction. Read More
Researchers at the Japanese Foundation for Cancer Research and RIKEN have disclosed tankyrase 1 (TNKS1; PARP5A) and/or TNKS2 (PARP5B) inhibitors reported to be useful for the treatment of cancer, metabolic disease, cartilage injury, multiple sclerosis, pulmonary fibrosis, amyotrophic lateral sclerosis, herpes simplex virus and Epstein Barr virus infections. Read More
Transcode Therapeutics Inc. has reported promising proof-of-concept laboratory studies in human cells, advancing its strategic partnership with Akribion Genomics AG. Read More
Nerviano Medical Sciences Srl has synthesized Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer, diabetic nephropathy, organ transplant rejection, arthritis, fibrosis, inflammation, neurodegeneration and metabolic diseases. Read More
Suzhou Kintor Pharmaceuticals Inc. has identified protein degradation inducers reported to be useful for the treatment of cancer, viral infection, cardiovascular and cerebrovascular disorders. Read More
Shanghai Allist Pharmaceuticals Co. Ltd. has divulged protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer. Read More
University of Toronto has described histone deacetylase 6 (HDAC6) inhibitors reported to be useful for the treatment of cancer and neurological disorders. Read More
Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd., has received approval from the FDA and China’s National Medical Products Administration (NMPA) to conduct clinical trials with SIM-0500 in patients with relapsed or refractory multiple myeloma. Read More
